Category: Biotechnology
Global Biotechnology
-
Advanced Authentication
... CAGR of 13.1% over the analysis period 2024-2030. Smart Cards, one of the segments analyzed in the report, is expected to record a 12.1% CAGR and reach US$18.7 Billion by the end of the analysis ... Read More
-
Bioinformatics
... 13.8% over the analysis period 2024-2030. Knowledge Management Tools, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$18.8 Billion by the end of the analysis period. ... Read More
-
Carbohydrase
... 5.6% over the analysis period 2024-2030. Amylases, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in ... Read More
-
Biological Drugs
... CAGR of 9.1% over the analysis period 2024-2030. Therapeutic Protein, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$289.1 Billion by the end of the analysis ... Read More
-
Diagnostic Specialty Enzymes
... at a CAGR of 6.2% over the analysis period 2024-2030. Polymerases & Nucleases, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$726.2 Million by the end ... Read More
-
Interferon
... 2.8% over the analysis period 2024-2030. Interferon Beta, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth ... Read More
-
Allografts
... 6.9% over the analysis period 2024-2030. Demineralized Bone Matrix (DBM), one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$488.4 Million by the end of the analysis ... Read More
-
Antisense and RNAi Therapeutics
... 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Antisense RNA, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.8 Billion by the ... Read More
-
Beta Interferon
... CAGR of 3.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$968.9 Million While China is Forecast to Grow at 4.5% CAGR The Beta Interferon market in the U.S. is estimated at ... Read More
-
Disposable Respirators
... CAGR of 4.5% over the analysis period 2024-2030. N-Series, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
IR Spectroscopy
... CAGR of 5.1% over the analysis period 2024-2030. Benchtop, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$647.6 Million by the end of the analysis period. ... Read More
-
Precision Medicine
... CAGR of 8.7% over the analysis period 2024-2030. Diagnostics, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$89.0 Billion by the end of the analysis period. ... Read More
-
Precision Medicine Software
... at a CAGR of 10.0% over the analysis period 2024-2030. On-Premise, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$2.6 Billion by the end of the ... Read More
-
Protein Sequencing
... CAGR of 2.9% over the analysis period 2024-2030. Mass Spectrometry, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$973.5 Million by the end of the analysis ... Read More
-
Custom Antibody
... CAGR of 9.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$320.3 Million by the end of the analysis ... Read More
-
Flow Imaging Microscopy/Dynamic Image Analysis
... Million by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$34.7 Million by ... Read More
-
Food Enzymes
... CAGR of 6.1% over the analysis period 2024-2030. Microorganisms, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.6 Billion by the end of the analysis period. ... Read More
-
Mammalian Polyclonal IgG Antibody
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Metabolic Markers, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$532.1 Million by the ... Read More
-
Stem Cell Banking
... at a CAGR of 7.5% over the analysis period 2024-2030. Placental and Cord Blood Stem Cells, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$10.5 Billion ... Read More
-
Soft Tissue Allografts
... at a CAGR of 4.9% over the analysis period 2024-2030. Orthopedic, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.9 Billion by the end of the ... Read More
-
Biosensors
... 7.2% over the analysis period 2024-2030. Non-wearable, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$28.3 Billion by the end of the analysis period. Growth in ... Read More
-
Cell and Tissue Culture Supplies
... Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$24.0 Billion by ... Read More
-
Nucleic Acid Testing
... at a CAGR of 4.5% over the analysis period 2024-2030. Nucleic Acid Test Kits, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$3.7 Billion by the ... Read More
-
Research ELISA (Enzyme-Linked Immunosorbent Assay)
... Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. ELISA Kits, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$478.6 Million ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the end ... Read More
Research Assistance
